Zdrowie i gospodarka · 28/07/2021

FDA Announces Generic Drug User Fee Rates for Fiscal Year 2022

The US Food and Drug Administration (FDA) has published the fiscal year 2022 rates for fees associated with the review of generic drug applications, as mandated by the Generic Drug User Fee Amendments of 2017 (GDUFA II). These fees support the FDA's efforts to ensure the safety and efficacy of generic medications.